| Literature DB >> 35983222 |
Yanhong Wu1, Zihao Guo1, Chuan Zhang2, Yutao Zhan2.
Abstract
Gastroesophageal reflux disease (GERD) is a common disease with increasing prevalence worldwide. However, the diagnosis of GERD is challenging because there are no definite gold standard criteria. Recently, a novel impedance parameter, namely mean nocturnal baseline impedance (MNBI), has been proposed, which reflects the burden of longitudinal reflux and the integrity of esophageal mucosa. MNBI has shown an immense promise for increasing the diagnostic rate of multichannel intraluminal impedance-pH (MII-pH) monitoring and predicting the response to proton pump inhibitor (PPI) or anti-reflux intervention in patients with reflux symptoms. The present paper reviews the association between baseline impedance and esophageal mucosal integrity, the acquisition of MNBI in 24-h MII-pH monitoring, the clinical utilization of MNBI in improving the diagnosis rate of GERD in patients with typical reflux symptoms, predicting the response to PPI or anti-reflux treatment in these patients, the utilization of MNBI in diagnosing patients with atypical symptoms or extra-esophageal symptoms, and the correlation between reflux burden and MNBI. MNBI should be routinely assessed using MII-pH monitoring.Entities:
Keywords: gastroesophageal reflux disease; mean nocturnal baseline impedance; multichannel intraluminal impedance-pH monitoring
Year: 2022 PMID: 35983222 PMCID: PMC9379274 DOI: 10.1177/17562848221105195
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.802
The association between BI and DIS.
| Author | Subject groups | DIS (μm) | BI (Ω) | AET (%) | Correlation | |
|---|---|---|---|---|---|---|
| DIS and BI | BI and AET | |||||
| Zhong | EE ( | 1.29 (1.10–1.46) | 1752 ± 1018 | 18.9 (10.1–27.9) | ||
| NERD ( | 1.10 (0.95–1.21) | 2640 ± 1143 | 6.4 (4.5–12.1) | |||
| Controls ( | 1.01 (0.94–1.17) | 3360 ± 1258 | 1.4 (0.6–3.0) | |||
| Kandulski | EE ( | – | 994.0 ± 182.2 | 6.1 ± 1.8 | ||
| NERD ( | – | 1558 ± 362.3 | 5.1 ± 1.0 | |||
| FH ( | – | 2884 ± 364.8 | 0.8 ± 0.2 | |||
| Xie | EE ( | 0.94 ± 0.17 | 1571.09 ± 567.54 | – | ||
| NERD ( | 0.89 ± 0.20 | 1581.07 ± 494.61 | – | |||
| RH ( | 0.85 ± 0.19 | 2156.01 ± 495.55 | – | |||
| Controls ( | 0.66 ± 0.11 | 2364.67 ± 500.70 | – | |||
AET, acid exposure time; BI, baseline impedance; DIS, dilated intercellular spaces; EE, erosive esophagitis; FH, functional heartburn; NERD, non-erosive reflux disease; RH, reflux hypersensitivity.
Figure 1.(a) Illustration of a 24-h MII-pH catheter with six impedance channels (Z1–Z6) (located at 17, 15, 9, 7, 5, and 3 cm above the LES, respectively) and an esophageal pH sensor. (b) The acquisition of MNBI. Three stable 10-min time periods (around 1 a.m., 2 a.m., and 3 a.m.) avoiding swallows, reflux episodes, artifacts, or pH drops are selected. The BI values of the three time periods are averaged to obtain the MNBI.
LES, lower esophageal sphincter; MII-pH, multichannel intraluminal impedance-pH; MNBI, mean nocturnal baseline impedance.
The utilization of MNBI in increasing the diagnostic rate of GERD and predicting the response to PPI or anti-reflux treatment in patients with typical reflux symptoms.
| Author | Off PPI or on PPI MII-pH | Subject groups | Group classification criteria | Assessment of the MNBI | MNBI (Ω) | Application of MNBI |
|---|---|---|---|---|---|---|
| Distinguishing GERD from Healthy controls | ||||||
| Frazzoni | Off PPI for at least 2 weeks | EE ( | With esophagitis | 3 cm above the LES | 1129 ± 654 | With an AUC 0.876 (95% CI 0.833–0.918) at a cutoff value of 2292 Ω |
| NERD ( | Normal endoscopy with positive pH or with negative pH | 1789 ± 812 | ||||
| HC ( | 2936 ± 772 | |||||
| Xie | Not mentioned | EE ( | With esophagitis | 5 cm above the LES | 1571.09 ± 567.54 | With an AUC 0.794 at a cutoff value of 1764 Ω |
| NERD ( | Normal endoscopy, but AET ⩾ 4% | 1581.07 ± 494.61 | ||||
| RH ( | Normal endoscopy, AET < 4% and SAP ⩾ 95% | 2156.1 ± 495.55 | ||||
| HC ( | 2364.67 ± 500.70 | |||||
| Frazzoni | Off PPI for 2 weeks | PPI dependent | Troublesome heartburn (score 2–3) | 3 cm above the LES | 1565 ± 837 | With an AUC 0.89 (95% CI 0.86–0.92) at a cutoff value of 2000 Ω |
| Heartburn ( | Suppressed (score 0–1) by 4-week standard-dosage PPI therapy, early recurring after PPI wash out and again early suppressed by 4-week standard-dosage PPI | |||||
| HC ( | 2990 ± 835 | |||||
| Separating NERD from FH | ||||||
| Tenca | Off-PPI for at least 10–14 days | NERD ( | Normal endoscopy findings and AET > 4.2% | 5 cm above the LES | 971 ± 180 | With an AUC 0.960 at a cutoff value of 2934 Ω, with a sensitivity of 88% and a specificity of 80% |
| FH ( | AET < 4.2%, normal total number of reflux events, and negative SAP/SI
| 3889 ± 728 | ||||
| Yoshimine | Not mentioned | NERD ( | AET > 4.2% or positive SI/SAP
| 5 cm above the LES | 2229.9 ± 1042.9 | With an AUC 0.73 (95% CI 0.63–0.84) at a cutoff value of 2874.1 Ω, with a sensitivity of 68.5% and a specificity of 72.8% |
| FH ( | AET < 4.2% and negative SI/SAP
| 3061.2 ± 762.1 | ||||
| Frazzoni | On PPI therapy | RRE ( | Persistence of mucosal breaks | 3 cm above the LES | 1145 (662–1879) | With an AUC 0.677 (95% CI 0.605–0.748), with a sensitivity of 43% and a specificity of 93% |
| HRE ( | Regressions of mucosal breaks | 1741 (1273–2951) | ||||
| NERD ( | Negative endoscopy findings, but AET > 3.2%, and/or number of reflux events <48, and/or positive SAP/SI
| 2374 (1755–2835) | ||||
| FH ( | Negative endoscopy findings, AET < 3.2%, number of reflux events <48, and negative SAP/SI
| 3488 (2965–4069) | ||||
| Frazzoni | Off PPI for 2 weeks | NERD ( | PPI-responsive heartburn, endoscopy negative, abnormal AET | 3 cm above the LES | 1378 ± 699 | With a sensitivity of 86% and a specificity of 94% |
| FH ( | Endoscopy-negative heartburn unaffected by PPI therapy, normal AET, and negative SAP/SI
| 3443 ± 873 | ||||
| Distinguishing RH from FH | ||||||
| Frazzoni | Off PPI for 2 weeks | RH ( | Negative upper endoscopy, normal AET, positive SAP/SI
| 3 cm above the LES | 2274 ± 774 | With an AUC 0.864 (95% CI 0.809–0.919), with a sensitivity of 56% and a specificity of 94% |
| FH ( | Endoscopy-negative heartburn unaffected by PPI therapy, normal AET, and negative SAP/SI
| 3443 ± 873 | ||||
| Gao | Off PPI for a week | FH ( | Normal endoscopy, normal AET, negative SAP/SI
| 3 cm above the LES | 2972.0 ± 775.6 | With an AUC 0.643 (95% CI 0.570–0.716) |
| RH ( | Normal endoscopy and AET, but positive SAP/SI
| 2485.3 ± 939.2 | ||||
| Identification of GERD | ||||||
| Jiang | Off anti-reflux therapy for at least 7 days | AET < 4% ( | The Lyon Consensus | 5 cm above the LES | 3388.5 ± 1639.5 | With an AUC 0.839 at a cutoff value of 1838 Ω, with a sensitivity of 76.6% and a specificity of 81.0% |
| AET 4–6% ( | 1911 ± 1464 | |||||
| AET > 6% ( | 1131 ± 1168 | |||||
| Ravi | Not mentioned | GERD ( | pH < 4 for ⩾5% of both the supine and total study time | 3 cm above the LES | 1331.3 ± 232.9 | With an AUC 0.891 at a cutoff value of 2268.1 Ω, with a sensitivity of 86.2% and a specificity of 80.8% |
| Controls ( | pH ⩽ 3% of the MII-pH study off PPI | 3397.4 ± 246 | ||||
| Hoshikawa | Off PPI for at least 7 days | EE ( | With esophagitis | 3 cm above the LES | 854 (509–1318) | Diagnosis of GERD (EE + NERD) with an AUC 0.872 at a cutoff value of 1785 Ω, with a sensitivity of 82.5% and a specificity of 89.7% |
| NERD ( | Negative endoscopy and AET > 6% | 1370 (812–1773) | ||||
| RH ( | Negative endoscopy, AET < 4%, and positive SAP/SI
| 2631 (1970–3680) | ||||
| FH ( | Negative endoscopy, AET < 4%, and negative SAP/SI
| 3200 (2270–4113) | ||||
| Wong | Off PPI for at least 7 days | GERD ( | EE or AET ⩾ 4% | 3 cm above the LES | 1385.2 ± 183.7 | With an AUC 0.865 at a cutoff value of 2128 Ω, with a sensitivity of 77.8% and a specificity of 84.2% |
| Non-GERD ( | No fulfillment above criteria | 2608.3 ± 123.1 | ||||
| Predicting the response to PPI or anti-reflux treatment | ||||||
| Frazzoni | After 2-week PPI withdrawal | PPI responsive ( | Troublesome heartburn (score 2–3) suppressed (score 0–1) by 4-week PPI therapy | 3 cm above the LES | 1681 ± 897 | Linking PPI-responsive heartburn to reflux better than AET (with AUC 0.742 |
| PPI refractory ( | Troublesome heartburn (score 2–3) unaffected by at least 8-week double-dosage PPI therapy | 2812 ± 1199 | ||||
| Ribolsi | Off PPI for at least 7 days | Responders ( | Symptom improvement ⩾50% | 3 cm above the LES | 1545.6 ± 826 Ω | Pathological MNBI (<2292 Ω) was significantly associated with PPI response |
| Non-responders ( | Symptom improvement <50% | 2385.9 ± 825.5 | ||||
| Patel | Off PPI for 5–7 days | Responder ( | ⩾50% improvement in GSS | The average of distal 4 channels | 1921.8 ± 127.1 | Predicting GSS improvement to anti-reflux therapy |
| Non-responder ( | Without ⩾50% GSS improvement | 2324.1 ± 197.1 | ||||
| Xie | Not mentioned | PPI effective ( | Symptom-free or with only one mild episode during the final week of the therapy otherwise the therapy was considered a failure | 5 cm above the LES | 1621.26 ± 561.17 | The BI >1764 Ω was the only independent predictor for the PPI failure |
| PPI failure ( | 2117.48 ± 428.68 | |||||
| Ribolsi | Off PPI for at least 7 days | Responders ( | Symptom improvement ⩾50% | 3 cm above the LES | 1607 ± 235 | Normal MNBI (>2292 Ω) was associated with an unfavorable response to PPIs |
| Non-responders ( | Symptom improvement <50% | 2108 ± 412 | ||||
| de Bortoli | Off PPI for 14 days | FH/PPI responders ( | ⩾50% Symptom improvement of FH patients | 3 cm above the LES | 1949.6 ± 548.8 | Identification of patients who respond to PPIs but would be classified as having FH |
| FH/PPI-non responders ( | <50% Symptom improvement of FH patients | 3812.8 ± 810.2 | ||||
| RH ( | Normal endoscopy, AET, number of reflux episodes, but positive SAP/SI
| 1839.7 ± 467.6 | ||||
SAP < 95% and SI < 50%.
SAP ⩾ 95% and/or SI ⩾ 50%.
AET, acid exposure time; AUC, area under the curve; CI, confidence interval; EE, erosive esophagitis; FH, functional heartburn; GERD, gastroesophageal reflux disease; GSS, global symptom severity; HC, healthy controls; HRE, healed reflux esophagitis; LES, lower esophageal sphincter; MII-pH, multichannel intraluminal impedance-pH; MNBI, mean nocturnal baseline impedance; NERD, non-erosive reflux disease; PPI, proton pump inhibitor; RH, reflux hypersensitivity; RRE, refractory reflux esophagitis; SAP, symptom association probability; SI, symptom index.